Novacyt announces update on strategic review of non-core assets NOVAprep® and clinical laboratory enter formal sales process Novacyt to enhance focus on core profitable diagnostic products business
Visit PageNews and Events
INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET ACTIONS COMPOSANT LE CAPITAL SOCIAL
Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers http://novacyt.com/wp-content/uploads/2018/12/NOVACYT_CP_Droits-de-vote_2018-Dec.pdf
Visit PageCompletion of substantial q16 molecular diagnostics order expands clinical diagnostic reach in fast growing Chinese market
Novacyt q16 order in China Paris, France and Camberley, UK – 6th December 2018 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces it has received another substantial order for Primerdesign’s q16 molecular instruments from a new customer within the fast growing Chinese market. The order for 100 molecular
Visit Page